SciClone Announces Enrollment Completion in Phase 2 Oral Mucositis Trial of SCV-07
SciClone Pharmaceuticals, Inc. has announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 — a small molecule synthetic peptide with immunomodulating properties — for the treatment of severe oral mucositis (OM) in patients with head and neck cancer. Topline results of the oral mucositis trial are expected to be announced in the first half of 2010.
- Oraya Therapeutics Initiates First Ever Sham-Controlled Study Of Radiation Therapy For Wet AMD
- Use of ultrasound, along with mammography, for breast cancers has benefits, risks
- Philips Unveils Two Major Innovations Designed To Help Radiologists Improve Patient Care
